Joel Baglole

Joel Baglole

InvestorPlace Contributor

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

4 Best Growth Stocks Flying Under the Radar

By Joel Baglole, InvestorPlace Contributor

There are many great growth stocks whose share prices have been beaten down despite reporting blowout quarterly results, having strong balance sheets, and providing positive forward guidance. Many of the hardest hit growth stocks have been of companies that are leaders in their respective markets. Here are four of the best growth stocks currently flying under the radar.

Buy Palantir Technologies Stock While It’s Still on Sale

By Joel Baglole, InvestorPlace Contributor

While it might not be every investor's cup of tea, Palantir's strong earnings and cheap share price make PLTR stock too good to ignore.

Fisker Looks Too Weak to Buy as EV and SPACs Keep Cooling Off

By Joel Baglole, InvestorPlace Contributor

Currently, FSR stock is trading at $10.29 a share, basically the same price it was at when it debuted on the New York Stock Exchange last fall. The share price has dropped 68% since hitting an all-time high of $31.96 on February 26th. Since then, the stock has fallen with the broader electric vehicle sector and downturn in SPAC-related securities, making now a bad time for investors to take a position.

Zomedica Stock Is Clearly Going to Keep Moving in the Wrong Direction

By Joel Baglole, InvestorPlace Contributor

The share price of the Ann Arbor, Michigan-based animal health company has now gone from a pullback and into a steep decline. Since March 15th, ZOM stock has fallen 68% and is now below the $1 threshold at just $0.79 per share. Given the precarious situation, investors should steer clear of this security for now.

4 Downtrodden Tech Stocks to Buy Today for A Big Bounceback

By Joel Baglole, InvestorPlace Contributor

While their share prices have been beaten down in recent months, these growth tech stocks still have a lot to offer investors.

Load More